- Home
- MLNK vs MNKD Comparison
MLNK vs MNKD Comparison
Compare MLNK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- MNKD
- Stock Information
- Founded
- MLNK 1998
- MNKD 1991
- Country
- MLNK United States
- MNKD United States
- Employees
- MLNK N/A
- MNKD N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- MNKD Health Care
- Exchange
- MLNK Nasdaq
- MNKD Nasdaq
- Market Cap
- MLNK 1.7B
- MNKD 1.8B
- IPO Year
- MLNK 2021
- MNKD 2004
- Fundamental
- Price
- MLNK $20.62
- MNKD $6.49
- Analyst Decision
- MLNK Hold
- MNKD Strong Buy
- Analyst Count
- MLNK 6
- MNKD 6
- Target Price
- MLNK $20.60
- MNKD $8.67
- AVG Volume (30 Days)
- MLNK 451.8K
- MNKD 2.1M
- Earning Date
- MLNK 10-30-2024
- MNKD 11-05-2024
- Dividend Yield
- MLNK N/A
- MNKD N/A
- EPS Growth
- MLNK N/A
- MNKD N/A
- EPS
- MLNK N/A
- MNKD 0.04
- Revenue
- MLNK $307,559,000.00
- MNKD $248,374,000.00
- Revenue This Year
- MLNK $6.13
- MNKD $48.01
- Revenue Next Year
- MLNK $7.71
- MNKD $14.08
- P/E Ratio
- MLNK N/A
- MNKD $149.89
- Revenue Growth
- MLNK 4.31
- MNKD 57.08
- 52 Week Low
- MLNK $14.89
- MNKD $3.17
- 52 Week High
- MLNK $25.88
- MNKD $6.92
- Technical
- Relative Strength Index (RSI)
- MLNK 36.19
- MNKD 61.52
- Support Level
- MLNK $19.72
- MNKD $6.14
- Resistance Level
- MLNK $23.41
- MNKD $6.70
- Average True Range (ATR)
- MLNK 0.74
- MNKD 0.20
- MACD
- MLNK -0.37
- MNKD -0.04
- Stochastic Oscillator
- MLNK 16.04
- MNKD 44.87
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.